Serina Therapeutics Announces Completion of Enrollment in the Phase Ia Trial of SER-214 in Parkinson’s Disease

Huntsville, AL, February 13th, 2017

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ™), announced today that the Phase Ia trial of SER-214 in Parkinson’s disease has completed enrollment. The Company intends to announce the results of the trial at future meetings in 2017.

“I am delighted to report that the Phase Ia trial in Parkinson’s disease has now completed enrollment. We anticipate the final cohort of data to be available in March and we plan to present this at upcoming scientific meetings in 2017,” announced Dr. Moreadith, President and CEO of Serina Therapeutics.

SER-214, a once-per-week subcutaneous administration of a POZ-conjugate of rotigotine, can be delivered in a standard insulin syringe. SER-214 is Serina’s most advanced clinical candidate. The preliminary data from the trial show that SER-214 is safe, well-tolerated and provides continuous drug delivery. Serina plans to advance SER-214 into Phase II development in the second half of 2017.

In addition to advancing its pipeline programs in pain, oncology, refractory seizures and inflammatory diseases, Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ platform and is actively seeking new partnerships.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that has developed novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology platform. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products.
for various pharmaceutical partners. POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus PEG and other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina has partnered its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit [www.serinatherapeutics.com](http://www.serinatherapeutics.com).